TY - JOUR
T1 - Comprehensive human urine standards for comparability and standardization in clinical proteome analysis
AU - Mischak, Harald
AU - Kolch, Walter
AU - Aivaliotis, Michalis
AU - Bouyssié, David
AU - Court, Magali
AU - Dihazi, Hassan
AU - Dihazi, Gry H.
AU - Franke, Julia
AU - Garin, Jérôme
AU - de Peredo, Anne Gonzalez
AU - IphÖfer, Alexander
AU - Jansch, Lothar
AU - Lacroix, Chrystelle
AU - Makridakis, Manousos
AU - Masselon, Christophe
AU - Metzger, Jochen
AU - Monsarrat, Bernard
AU - Mrug, Michal
AU - Norling, Martin
AU - Novak, Jan
AU - Pich, Andreas
AU - Pitt, Andrew
AU - Bongcam-Rudloff, Erik
AU - Siwy, Justyna
AU - Suzuki, Hitoshi
AU - Thongboonkerd, Visith
AU - Wang, Li Shun
AU - Zoidakis, Jérôme
AU - Zu.rbig, Petra
AU - Schanstra, Joost P.
AU - Vlahou, Antonia
PY - 2010/3/26
Y1 - 2010/3/26
N2 - Purpose: Urine proteomics is emerging as a powerful tool for biomarker discovery. The purpose of this study is the development of a well-characterized "real life" sample that can be used as reference standard in urine clinical proteomics studies. Experimental design: We report on the generation of male and female urine samples that are extensively characterized by different platforms and methods (CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS (using LTQ-FT ultra), and 2-DE-MS) for their proteome and peptidome. In several cases analysis involved a definition of the actual biochemical entities, i.e. proteins/peptides associated with molecular mass and detected PTMs and the relative abundance of these compounds. Results: The combination of different technologies allowed coverage of a wide mass range revealing the advantages and complementarities of the different technologies. Application of these samples in "inter-laboratory" and "inter-platform" data comparison is also demonstrated. Conclusions and clinical relevance: These well-characterized urine samples are freely available upon request to enable data comparison especially in the context of biomarker discovery and validation studies. It is also expected that they will provide the basis for the comprehensive characterization of the urinary proteome.
AB - Purpose: Urine proteomics is emerging as a powerful tool for biomarker discovery. The purpose of this study is the development of a well-characterized "real life" sample that can be used as reference standard in urine clinical proteomics studies. Experimental design: We report on the generation of male and female urine samples that are extensively characterized by different platforms and methods (CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS (using LTQ-FT ultra), and 2-DE-MS) for their proteome and peptidome. In several cases analysis involved a definition of the actual biochemical entities, i.e. proteins/peptides associated with molecular mass and detected PTMs and the relative abundance of these compounds. Results: The combination of different technologies allowed coverage of a wide mass range revealing the advantages and complementarities of the different technologies. Application of these samples in "inter-laboratory" and "inter-platform" data comparison is also demonstrated. Conclusions and clinical relevance: These well-characterized urine samples are freely available upon request to enable data comparison especially in the context of biomarker discovery and validation studies. It is also expected that they will provide the basis for the comprehensive characterization of the urinary proteome.
KW - CClinical proteomics
KW - Proteome
KW - Standard
KW - Urine
UR - http://www.scopus.com/inward/record.url?scp=77953722868&partnerID=8YFLogxK
U2 - 10.1002/prca.200900189
DO - 10.1002/prca.200900189
M3 - Article
C2 - 21137064
AN - SCOPUS:77953722868
SN - 1862-8346
VL - 4
SP - 464
EP - 478
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
IS - 4
ER -